Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia, Tobacco Use Disorder

In brief

Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.

Key facts

Study ID

NCT00218231

Run by

National Institute on Drug Abuse (NIDA)

People needed

48

Starts

2004-01-01

Expected to finish

2006-08-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosed with schizophrenia or schizo-affective disorder
• Smokes between 20 and 50 cigarettes per day
• Moderate to high nicotine dependence score
• Interest in quitting smoking

You may not qualify if…

• Currently trying to quit smoking
• Seizure disorder or lowered seizure threshold due to anorexia, bulimia, head trauma, diabetes with insulin, or hypoglycemics
• Alcohol or drug use disorders
• Requires certain medications
• Pregnant or breastfeeding

Where it is running

• Providence VA Medical Center, RI — Providence, Rhode Island, United States
• Brown University — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.